What Is Hexarelin?
Hexarelin is a laboratory-made peptide containing six amino-acid residues. It activates the ghrelin receptor, a signalling protein involved in growth hormone release, appetite, glucose regulation and several other body systems. Examorelin is the international non-proprietary name used for the same active molecule.
Researchers developed hexarelin in the early 1990s by modifying an older compound called GHRP-6. Small human experiments then examined how strongly it released growth hormone, how different routes changed the response and whether repeated exposure weakened that response. Other teams used it to study heart function, childhood growth and sleep. These studies show that hexarelin is biologically active in people. They do not establish it as a treatment for muscle gain, fat loss, recovery, sleep, heart disease or healthy ageing.
Hexarelin is not growth hormone, a steroid or an approved medicine. A short-lived rise in a hormone or in the amount of blood pumped from the heart is not the same as a lasting improvement in health. The human studies were generally small, many were conducted about three decades ago, and most measured laboratory or imaging outcomes rather than symptoms, function or survival.
What exactly is hexarelin?
Hexarelin is a growth hormone secretagogue. A secretagogue is a substance that prompts a gland to release a hormone it already stores. In this case, the main measured response is the release of growth hormone from the pituitary gland, a small hormone-producing organ at the base of the brain.
The commonly reported sequence is His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. Written out, the chain contains histidine, D-2-methyltryptophan, alanine, tryptophan, D-phenylalanine and lysine. The final NH2 shows that the end of the peptide is amidated. Amidation replaces the usual acidic end with an amide group and can change stability and biological activity.
The chain has six residues. A residue is what an amino acid is called after it has been joined into a peptide. Two residues use the D orientation, and one of them is also methylated. D-amino acids are mirror-image forms of the L-amino acids normally used to build human proteins. Methylation adds a small carbon-containing group. These changes help explain why hexarelin is not a natural human peptide and why it can resist some enzymes that would cut an ordinary peptide apart.
Chemical databases report a molecular formula of C47H58N12O6 and a molecular mass of about 887 daltons for the uncharged peptide. A dalton is a unit used for the mass of atoms and molecules. A finished material may be supplied as an acetate or another salt, which changes the total mass of the material in a vial without changing the six-residue active chain.
Examorelin is the recognised generic name. EP-23905 and MF-6003 are development codes found in older records. Hexarelin is the name used most often in the research literature. These labels may point to the same active sequence, but they do not prove that two finished products have the same purity, salt, sterility, concentration or stability.
Is hexarelin growth hormone, GHRH or a steroid?
No. Hexarelin can prompt growth hormone release, but it is not growth hormone itself.
Human growth hormone is a protein containing 191 amino acids. It is produced by the pituitary gland and acts directly on tissues as well as through insulin-like growth factor 1, usually shortened to IGF-1. IGF-1 is a hormone involved in normal growth and tissue maintenance.
Growth hormone-releasing hormone, shortened to GHRH, is a natural 44-amino-acid hormone made by the hypothalamus, a region of the brain that helps control the endocrine system. GHRH activates the GHRH receptor. Hexarelin activates the ghrelin receptor. The two signals can reinforce one another, but they are not the same molecule and do not use the same receptor.
Hexarelin is also not an anabolic steroid. Anabolic steroids are testosterone-related compounds that act through androgen receptors. Hexarelin has a peptide structure and a different biological target. Being non-steroidal does not establish safety or usefulness.
How does the normal growth hormone system work?
Growth hormone is released in pulses rather than at a steady rate. The hypothalamus helps control those pulses through several signals. GHRH encourages release. Somatostatin restrains it. Somatostatin is a natural hormone that reduces the release of several other hormones.
Specialised pituitary cells called somatotrophs store growth hormone. When the balance of signals favours release, growth hormone enters the blood. It can act directly and can prompt the liver and other tissues to make IGF-1. Growth hormone and IGF-1 then feed information back to the hypothalamus and pituitary.
Sleep, age, nutritional state, body fat, exercise, sex hormones, glucose and illness all affect this system. A person can therefore produce different responses to the same laboratory challenge on different occasions. A large growth hormone peak after one research administration does not show that repeated exposure will produce the same peak or a useful change in body composition, strength or wellbeing.
Ghrelin adds another layer. It is a natural hormone made mainly in the stomach. Its active form carries a fatty-acid group that allows it to activate the ghrelin receptor. Ghrelin influences appetite, stomach movement, glucose regulation and growth hormone release.
Hexarelin activates the ghrelin receptor without copying ghrelin's structure. An agonist is a molecule that switches a receptor on. The receptor is present in the pituitary and brain, and related binding sites have been measured in other tissues. This wider biology is one reason hexarelin cannot be understood as a perfectly selective growth hormone switch.
What is hexarelin made from?
Hexarelin is assembled from six protected amino-acid derivatives:
- L-histidine at position one.
- D-2-methyltryptophan at position two.
- L-alanine at position three.
- L-tryptophan at position four.
- D-phenylalanine at position five.
- L-lysine at position six.
- An amide group at the end of the chain.
Histidine, alanine, tryptophan, phenylalanine and lysine are amino acids found in human proteins. D-2-methyltryptophan is a modified, mirror-image building block selected to change receptor activity and resistance to breakdown. The peptide is produced from chemical raw materials. It is not extracted from human pituitary tissue, blood, stomach or growth hormone.
The exact order and orientation matter. A chain with the same ingredients in a different order is a different molecule. A material with L-phenylalanine instead of D-phenylalanine, or ordinary D-tryptophan instead of D-2-methyltryptophan, may have a different shape and biological effect.
How is hexarelin synthesised and manufactured?
Hexarelin can be made by solid-phase peptide synthesis. In this method, one end of the growing peptide remains attached to an insoluble resin bead while the manufacturer adds one protected amino-acid derivative at a time.
Temporary protective groups cover the reactive parts that should not join during a particular step. Each cycle removes one protective group, activates the next building block and forms a peptide bond. Coupling reagents help create that bond. Solvents and repeated washes remove unused material and reaction by-products before the next cycle.
The raw materials include protected histidine, D-2-methyltryptophan, alanine, tryptophan, D-phenylalanine and lysine. They also include the resin, coupling reagents, bases, solvents and the chemical arrangement required to produce the terminal amide. The identity and purity of the unusual D-2-methyltryptophan building block are especially important because ordinary mass measurement may not reveal the wrong three-dimensional orientation.
After assembly, strong reagents release the peptide from the resin and remove most remaining protective groups. The crude material is a mixture. It can contain the intended chain, shorter chains missing one residue, incompletely deprotected material, products damaged by oxidation and chemicals left from manufacture.
Preparative high-performance liquid chromatography, shortened to HPLC, can separate the main peptide from many impurities. Analytical HPLC estimates the proportion of separated components. Mass spectrometry measures mass-to-charge patterns and can support confirmation of the expected molecular mass. Peptide mapping, amino-acid analysis and methods designed to check stereochemistry may be needed to establish more of the identity.
The purified peptide may be converted to a salt and freeze-dried. Freeze-drying removes water at low temperature and reduced pressure. It does not make the material sterile, remove endotoxins or prove that the correct amount is present. Endotoxins are inflammatory components from bacteria that can remain after living bacteria have been removed.
For a product intended for injection, manufacture would also require validated controls for sterility, endotoxins, visible and subvisible particles, concentration and container integrity. Stability testing would need to examine whether the peptide oxidises, breaks down or forms aggregates. An aggregate is a cluster of peptide molecules. Aggregates can change biological activity and may increase the risk of an unwanted immune response.
A headline purity percentage is not a complete quality assessment. It may describe only the area of the main HPLC peak. It does not by itself establish the sequence, D and L orientation, amount, salt, sterility, endotoxin level, stability or suitability for use in people.
When was hexarelin first documented?
Hexarelin came from the same research programme that produced GHRP-6 and other synthetic growth hormone-releasing peptides. Scientists were changing short peptide structures to find stronger and more stable signals for pituitary growth hormone release.
The molecule was being discussed under development codes by the early 1990s. A 1992 scientific meeting abstract is cited in the development record, and the first detailed human papers appeared in 1994. One tested increasing intravenous levels in 12 healthy young men. Another compared intravenous, subcutaneous, intranasal and oral exposure in healthy volunteers.
The order of discovery matters. Researchers studied hexarelin before the ghrelin receptor had been fully identified and before its natural hormone was known. Scientists cloned the growth hormone secretagogue receptor in 1996. They discovered ghrelin in 1999. Hexarelin therefore helped researchers find and investigate a signalling system whose natural ligand was identified later.
Human research expanded during the 1990s. Studies examined age, body composition, growth hormone deficiency, childhood short stature, repeated exposure and interactions with GHRH. Small cardiac physiology experiments appeared around 1999 to 2002. A sleep study was published in 2004.
The programme did not lead to a widely approved medicine. Current interest is driven largely by the old physiology record, later laboratory research and commercial discussion rather than by a modern clinical development programme showing patient benefit.
| Year | Development |
|---|---|
| Early 1990s | Hexarelin was developed as a modified GHRP-6 analogue |
| 1994 | Human dose-response and route-comparison studies were published |
| 1995 to 1998 | Researchers studied age, body composition, pituitary reserve and repeated exposure |
| 1996 | Scientists cloned the growth hormone secretagogue receptor |
| 1999 | Ghrelin was identified as the receptor's natural hormone |
| 1999 to 2002 | Small human experiments measured short-term cardiac effects |
| 2004 | A seven-person controlled study examined sleep and overnight hormones |
| Current position | Hexarelin remains an investigational compound without an approved medical use |
How does hexarelin work?
Hexarelin binds to the active ghrelin receptor, usually written as GHS-R1a. The receptor belongs to a family of proteins that cross the cell membrane and pass a signal inside when activated.
On pituitary somatotrophs, receptor activation changes signalling inside the cell and raises calcium. Calcium helps trigger the release of stored growth hormone. Hexarelin also acts through the hypothalamus, where it interacts with the natural balance between GHRH and somatostatin.
Human experiments found that hexarelin and GHRH could produce a stronger growth hormone response together than either produced alone. Researchers call this synergy. It helped show that the signals use separate but connected routes. It does not show that combining compounds is a useful or safe treatment.
Hexarelin can also influence other pituitary pathways. Some human experiments measured rises in prolactin, adrenocorticotropic hormone and cortisol. Prolactin has roles in breast development and milk production as well as other functions. Adrenocorticotropic hormone, shortened to ACTH, tells the adrenal glands to release cortisol. Cortisol helps the body respond to stress and affects metabolism, blood pressure and immune activity.
Older binding experiments found hexarelin-recognising sites in heart tissue and other organs. Some of this binding was linked to CD36, a membrane protein involved in fatty-acid handling and other cell functions. These findings are mechanistic clues. They do not prove that administering hexarelin protects a human heart.
What human research exists?
The human record can be divided into five groups:
- Acute studies measuring growth hormone and other hormone responses after one exposure.
- Route and pharmacology studies comparing intravenous, subcutaneous, intranasal and oral exposure.
- Repeated-exposure studies examining whether the hormone response weakens and whether IGF-1 or body composition changes.
- Paediatric and diagnostic studies in short children or people with suspected growth hormone deficiency.
- Small cardiac and sleep experiments measuring short-term physiological changes.
Most studies were exploratory and involved small numbers. An exploratory study is designed to learn about signals and generate questions rather than provide a final answer about treatment. Many used growth hormone concentration, IGF-1 or left ventricular ejection fraction as the main outcome.
These are biomarkers or physiological measurements. A biomarker is a measurable biological sign. A change can help show that a compound reached a pathway, but it does not automatically show that participants became healthier, stronger, leaner or less likely to experience disease.
There is no large modern programme establishing hexarelin for a medical condition. The evidence is much stronger for an immediate hormone response than for any clinical benefit.
What did the first human dose-response study find?
The 1994 dose-response study enrolled 12 healthy young men. It was double-blind and placebo-controlled. Double-blind means that the participants and the investigators assessing them did not know which administration was active at the time. A placebo is an inactive comparison designed to help separate a compound's effect from expectation and ordinary biological variation.
The men received rising intravenous research levels from 0.25 to 2 micrograms per kilogram of body weight, as well as placebo. Intravenous means that the material was delivered directly into a vein. Growth hormone increased with the administered level, and the response approached a maximum near the highest level tested.
The estimated maximum growth hormone concentration was 55.1 nanograms per millilitre. A nanogram is one billionth of a gram. The estimated area under the concentration-time curve was 3,936 nanogram-minutes per millilitre. Area under the curve summarises total measured exposure or response across time rather than using only the highest point.
The experiment established an acute biological effect under controlled conditions. It did not test a disease, repeated use, body composition, strength, recovery or long-term safety. Twelve healthy young men cannot represent women, older adults, children or people with endocrine, glucose or heart conditions.
How did the route of exposure change the response?
A second 1994 paper enrolled 12 healthy young volunteers and compared several routes. Researchers studied intravenous levels of 1 and 2 micrograms per kilogram, subcutaneous levels of 1.5 and 3 micrograms per kilogram, an intranasal level of 20 micrograms per kilogram and oral levels of 20 and 40 milligrams.
Subcutaneous means beneath the skin. Intranasal means delivered through the nose. Oral means swallowed. The large difference between the numbers for different routes is not a set of equivalent doses. It reflects the different proportions that reached the circulation and the design of that experiment.
The study found growth hormone responses after all four routes. The subcutaneous response increased between the two levels tested. Oral and intranasal exposure were much less efficient than intravenous exposure. Later work estimated oral biological availability at about 0.3 per cent when judged by the growth hormone response. Biological availability here means the fraction of the response achieved after swallowing compared with intravenous exposure, not simply the amount chemically detected in blood.
These findings are sometimes presented online as administration guidance. They are not. They are historical research observations from small, medically supervised experiments using defined study material. They do not establish an appropriate level, product or route for an individual.
What happened with repeated exposure?
Repeated exposure did not simply reproduce the first response unchanged.
In one 16-week study, participants received subcutaneous hexarelin twice daily at a research level of 1.5 micrograms per kilogram. The growth hormone response to a test administration became partly weaker by week 16. Four weeks after exposure stopped, the response had recovered towards its starting level. This is described as partial and reversible attenuation. Attenuation means that the response became smaller.
Serum IGF-1 and IGF-binding protein 3 did not change significantly across the 20-week observation period. IGF-binding proteins carry and regulate IGF-1 in the circulation. Total body fat, lean body mass and bone mineral density also did not change significantly at week 16.
These findings matter because the online rationale often runs from a short growth hormone peak to an assumption of higher IGF-1, less fat or more lean tissue. This study did not show that chain of outcomes. The biological effect on the growth hormone and IGF-1 system was described by the investigators as minimal under the schedule they tested.
Another study measured 24-hour growth hormone patterns during two or three daily subcutaneous administrations. It found an increase in the amount of growth hormone released in pulses without a clear 24-hour rise in prolactin, ACTH or cortisol. That result shows why timing and repeated sampling matter. A brief post-administration rise and an average across a full day answer different questions.
The studies were still small and were not designed to establish clinical benefit or uncommon harms. A response that becomes weaker also makes it unsafe to assume that more exposure will preserve or restore an effect.
Do age and body composition affect the response?
Yes. Growth hormone physiology changes with age, puberty and body composition, and hexarelin studies reflected those differences.
A study of 96 children compared 52 prepubertal children with 44 who had entered puberty. Puberty is the period in which sex hormones rise and the body matures reproductively. Responses to an intravenous research challenge differed with pubertal stage, showing that one threshold cannot be transferred freely across ages.
Other research compared children, adults and older people. The growth hormone response was generally stronger around puberty and young adulthood and weaker in older age. This pattern is consistent with ordinary age-related changes in the growth hormone system.
Body fat also matters. One study found that greater total fat mass was associated with a smaller growth hormone response after subcutaneous hexarelin. That finding does not show that hexarelin reduces fat. It shows that the starting physiology of participants can change a hormone test result.
Sex hormones may also change responsiveness. Studies examining testosterone or oestrogen exposure were designed to understand endocrine regulation. They should not be treated as evidence for combining substances.
What did studies in children find?
Paediatric research included hormone challenge tests and a few small repeated-exposure studies. It does not establish a current approved treatment.
One uncontrolled study enrolled eight prepubertal children with short stature, aged between 4 and 11.6 years. Prepubertal means that they had not yet entered puberty. They received intranasal hexarelin three times daily for up to eight months at the level stated in the paper. There was no placebo group and no random assignment.
Mean IGF-1 increased from 10.4 to 14.1 nanomoles per litre, and average annualised growth velocity increased from 5.3 to 8.3 centimetres per year. Annualised growth velocity estimates how far a child would grow over a year from the observed period. In eight children without a comparison group, it is difficult to separate treatment, ordinary variation, measurement, age and regression towards the average.
Another 16-week study examined repeated exposure and endocrine responses. Cortisol response declined by week 16 and recovered after exposure stopped. The investigators did not find evidence of continuing adrenal over-stimulation, but the study was not large or long enough to rule out uncommon or delayed harms.
Diagnostic studies asked whether a one-time hexarelin challenge could reveal remaining pituitary growth hormone reserve. A diagnostic challenge and a treatment are different. A test may be useful because it produces a temporary measurable signal. That does not mean repeated exposure improves growth or health.
Modern evaluation of a treatment for childhood growth would require randomised comparison, a defined diagnosis, growth measurements over sufficient time, assessment of puberty and bone age, and careful monitoring of glucose, IGF-1 and other pituitary hormones. Bone age is an X-ray estimate of skeletal maturity.
What did the cardiac studies find?
Several small experiments reported short-term changes in cardiac measurements. They did not show that hexarelin prevents heart attacks, treats heart failure or improves survival.
The most frequently discussed outcome was left ventricular ejection fraction, shortened to LVEF. The left ventricle is the heart's main pumping chamber. Ejection fraction is the percentage of blood in that chamber pumped out with each contraction. It can rise temporarily without showing that a treatment changes symptoms or long-term disease.
In one study, seven healthy men received recombinant human growth hormone or hexarelin on separate occasions. Recombinant means made using engineered living cells. Hexarelin increased mean LVEF from 64.0 to 70.7 per cent during the short observation period. Growth hormone did not produce the same acute change. The experiment was too small and brief to assess clinical outcomes.
Another study compared seven healthy participants, seven adults with severe growth hormone deficiency and 12 people with severe dilated cardiomyopathy. Dilated cardiomyopathy is a condition in which the heart's main pumping chamber becomes enlarged and weak. A single intravenous challenge increased LVEF in the healthy and growth hormone-deficient groups. It did not establish a significant benefit in the dilated cardiomyopathy group.
An eight-person study in dilated cardiomyopathy and a five-person study in ischaemic cardiomyopathy suggested that the immediate response might differ by cause of heart disease. Ischaemic cardiomyopathy is weakness caused by reduced blood supply, often after coronary artery disease or a heart attack. These tiny groups are useful for forming hypotheses, not for directing treatment.
Researchers also studied people during coronary artery bypass surgery. Coronary bypass uses blood vessels from elsewhere in the body to route blood around narrowed heart arteries. Acute haemodynamic measurements suggested that hexarelin could change pumping measures under anaesthesia. Haemodynamic means related to blood flow and pressure. This was not a trial of recovery, complications or survival.
Laboratory and animal work proposed effects through heart binding sites, CD36, blood-vessel resistance or protection from experimental injury. Those mechanisms are not substitutes for a clinical trial. No large randomised study has shown that hexarelin helps people with heart disease.
Does hexarelin improve sleep?
The controlled human study does not support a simple sleep-improvement claim.
Seven healthy young volunteers took part in an overnight experiment. On one night they received four intravenous administrations of 50 micrograms, one each at 10 pm, 11 pm, midnight and 1 am. On another night they received placebo. Sleep was measured with polysomnography, a method that records brain activity, eye movements, muscle activity and other signals to identify sleep stages.
Hexarelin increased growth hormone, ACTH, cortisol and prolactin. It decreased slow-wave sleep. Slow-wave sleep is the deepest part of non-rapid-eye-movement sleep and is often described as deep sleep. A reduction is not evidence of better sleep quality.
This was a seven-person, single-night study. It cannot establish chronic effects, but it directly challenges claims that growth hormone release automatically improves sleep. Hormone release during sleep and restorative sleep are related aspects of physiology, not interchangeable outcomes.
What do cell and animal studies add?
Preclinical research means work conducted before or outside human clinical trials. It can show mechanisms worth testing, but the findings cannot be assumed to occur in people.
Cell studies examined receptor signalling, calcium movement and binding in pituitary or heart-related cells. They helped identify where hexarelin might act. A concentration placed directly on cells does not reproduce absorption, breakdown, distribution or immune effects in a whole person.
Animal studies explored experimental heart injury, blood-vessel resistance and protection during reduced blood flow. Some rat studies reported improved cardiac function after experimental myocardial infarction. A myocardial infarction is a heart attack caused by loss of blood supply to heart muscle. These were controlled models with specific timing and laboratory conditions.
Other animal work examined food intake, body weight and tissue effects associated with ghrelin-receptor activation. Species differ in receptor distribution, hormone feedback and metabolism. A result in a rat cannot define a human benefit or safe exposure.
The human cardiac experiments are sometimes used to bridge the animal findings. They show a temporary change in a pumping measurement, not prevention of damage or improvement in disease. The bridge remains incomplete.
What administration levels have appeared in published research?
The following table records selected study conditions so that their findings can be interpreted. It is not a dosing guide. The studies used defined research material, eligibility checks, monitoring and routes selected for experimental questions.
| Study | Participants | Documented research exposure | What the study measured |
|---|---|---|---|
| 1994 dose-response study | 12 healthy young men | Single intravenous levels from 0.25 to 2 micrograms per kilogram, plus placebo | Growth hormone concentration and total response over time |
| 1994 route comparison | 12 healthy young volunteers | Intravenous 1 or 2 micrograms per kilogram; subcutaneous 1.5 or 3 micrograms per kilogram; intranasal 20 micrograms per kilogram; oral 20 or 40 milligrams | Growth hormone response by route |
| Repeated-exposure study | Small adult study | Subcutaneous 1.5 micrograms per kilogram twice daily for 16 weeks | Growth hormone responsiveness, IGF-1, body composition and bone measures |
| Paediatric growth study | Eight prepubertal short children | Intranasal 60 micrograms per kilogram three times daily for up to eight months | IGF-1 and growth velocity; no placebo group |
| Sleep study | Seven healthy young volunteers | Four intravenous administrations of 50 micrograms over one night, compared with placebo | Sleep stages, growth hormone, ACTH, cortisol and prolactin |
| Cardiac physiology studies | Very small healthy and cardiac groups | Usually one intravenous challenge, often 2 micrograms per kilogram | Short-term LVEF and haemodynamic measures |
Micrograms and milligrams are units of mass. One milligram equals 1,000 micrograms. A per-kilogram level scales the amount to body weight. The presence of these numbers in published papers does not make them recommendations. It also does not show that a different product, route or person would have the same exposure.
Does hexarelin build muscle or reduce body fat?
Human evidence does not establish either outcome.
The case for muscle gain is usually indirect: hexarelin raises growth hormone, growth hormone can influence IGF-1, and the growth hormone and IGF-1 system is involved in tissue growth. Each step is biologically real, but the full conclusion requires trials that measure muscle mass, strength and function.
The 16-week study did not find a significant change in lean body mass, total body fat or bone mineral density. IGF-1 also did not change significantly. That is more relevant to a repeated-use claim than a growth hormone peak after one intravenous challenge.
Growth hormone responses are often smaller in people with more body fat. This association should not be reversed into evidence that hexarelin reduces fat. No controlled weight-loss programme has established a clinically useful change in weight, waist, visceral fat or metabolic health.
There is also no controlled human evidence that hexarelin improves athletic performance, recovery between training sessions or the healing of muscle, tendon or ligament injuries.
Does hexarelin treat growth hormone deficiency?
No approved treatment role has been established.
Some studies used hexarelin as a provocative test. A provocative test gives a substance once and measures whether the pituitary can respond. Growth hormone deficiency can be difficult to diagnose because normal release is pulsatile. A random blood sample may be low even in a healthy person.
A challenge can therefore help researchers estimate remaining pituitary reserve. It does not replace a complete endocrine assessment, validated diagnostic thresholds or an approved test. It also does not show that repeated hexarelin is an effective replacement for prescribed growth hormone in a person with confirmed deficiency.
Diagnostic and therapeutic questions must remain separate. The ability to release some stored hormone once does not show that a person produces enough growth hormone across ordinary life or that repeated stimulation will correct the consequences of deficiency.
What safety concerns are known?
The safety record is incomplete. Small experiments can describe common immediate reactions, but they are poorly suited to finding uncommon, delayed or long-term harms.
Potential concerns arise from the measured biology:
- Growth hormone and IGF-1 signalling: Persistent stimulation could affect glucose regulation, fluid balance and tissues that respond to growth signals. The published repeated-exposure study did not show a sustained IGF-1 rise, but it cannot rule out different responses in other people or with other exposure.
- Cortisol and prolactin: Acute studies measured increases in cortisol and prolactin as well as growth hormone. These are not necessarily harmless side observations, particularly for people with endocrine conditions.
- Glucose control: Growth hormone can reduce insulin sensitivity. Insulin sensitivity describes how effectively insulin helps move glucose from the blood into cells. Trials were not designed to establish long-term metabolic safety in people with diabetes or prediabetes.
- Desensitisation: The growth hormone response became partly weaker after repeated exposure. Escalating exposure in response would not be evidence-based and could increase other risks.
- Heart disease: Temporary ejection-fraction changes do not establish safety in people with arrhythmias, coronary disease, cardiomyopathy or heart failure. An arrhythmia is an abnormal heart rhythm.
- Immune reactions: Synthetic peptides and their aggregates or impurities may trigger antibodies or allergic reactions. The small studies cannot define that risk for unapproved products.
- Product quality: Wrong sequence, incorrect stereochemistry, oxidation, contamination, endotoxin, particles or inaccurate concentration can add risks that do not appear in a study using characterised material.
Headache, flushing, tiredness, nausea, local reactions or appetite changes may be biologically plausible and are reported across the wider secretagogue literature, but hexarelin does not have a modern approved label that provides reliable event rates for a defined product. It would be misleading to present an online side-effect list as though the probabilities were known.
The absence of a serious event in a study of seven or 12 people is weak reassurance. If a harm occurs in one person out of several hundred, a small study will probably miss it.
Could growth signalling matter in cancer?
There is no clinical evidence that hexarelin treats cancer. The safety question is different: growth hormone and IGF-1 are involved in cell growth, so unnecessary stimulation is a concern when a person has an active or previous tumour.
Receptor or cell experiments cannot predict the net effect in a person. Tumours differ, and cancer treatment can alter the heart, liver, kidneys and endocrine system. A product impurity or immune response creates separate risks.
Hexarelin has not undergone the long, condition-specific clinical testing needed to define cancer-related safety. People with a cancer history, pituitary tumour or unexplained hormone abnormality should not infer safety from short experiments in healthy volunteers.
Is hexarelin approved as a medicine?
Hexarelin is not an FDA-approved medicine. We did not identify a current EMA-authorised product containing examorelin. It should be described as investigational, not as an approved treatment for growth hormone deficiency, heart disease, body composition or ageing.
FDA approval applies to a defined product, manufacturer, formulation and use. A chemical name appearing in a database, paper, patent or enforcement record is not approval.
Compounded drugs are also not FDA approved. Compounding is the preparation of a medicine for a patient under particular legal conditions. FDA does not review a compounded drug's safety, effectiveness and quality before marketing in the same way that it reviews an approved product.
We did not find hexarelin named on FDA's current page of bulk substances that may present significant safety risks. That absence must not be read as clearance or approval. General risks associated with an unapproved peptide and its manufacture remain.
Is hexarelin prohibited in sport?
Yes. The World Anti-Doping Agency, commonly called WADA, names examorelin, with hexarelin in brackets, among growth hormone secretagogues prohibited at all times. For athletes covered by the World Anti-Doping Code, at all times means both in and out of competition.
The rule does not depend on whether a product is marketed as a research chemical or supplement. Athletes are responsible for prohibited substances found in their samples. Anti-doping rules and therapeutic-use-exemption requirements can change, so current official information matters.
What product-quality questions matter?
The word hexarelin on a label does not establish what is in a container. A meaningful assessment would ask:
- Is the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2?
- Are D-2-methyltryptophan and D-phenylalanine present in the correct positions and orientation?
- Is the C-terminal amide present?
- Which salt and counterions are present?
- Are deletion sequences, oxidation products, residual solvents and aggregates controlled?
- Does the container hold the stated amount?
- Has stability been measured under the stated conditions?
- For an injectable product, have sterility, endotoxin and particle controls been validated?
An analytical certificate can be useful, but it must be interpreted. One HPLC purity number does not prove every element. Independent identity testing, quantitative analysis and methods suitable for stereochemistry are separate from tests for microorganisms and endotoxins.
A research-use-only label is a commercial statement, not a biological protection. If material enters a person, impurities and contamination can still cause harm.
How does hexarelin compare with related compounds?
| Compound | Main receptor route | Strongest human evidence | Regulatory position |
|---|---|---|---|
| Hexarelin / examorelin | Ghrelin receptor | Small endocrine, paediatric, sleep and cardiac physiology studies | Investigational and unapproved |
| GHRP-6 | Ghrelin receptor | Small endocrine studies and an unsuccessful EGF-combination stroke programme | Unapproved in the US |
| GHRP-2 / pralmorelin | Ghrelin receptor | Endocrine studies and an approved diagnostic role in Japan | Japanese diagnostic medicine; not FDA approved |
| Ipamorelin | Ghrelin receptor | Early pharmacology and unsuccessful postoperative bowel-recovery development | Unapproved |
| Sermorelin | GHRH receptor | Older diagnostic and paediatric research on GHRH(1-29) | Former US medicine; current compounded products are not approved |
| Tesamorelin | GHRH receptor | Controlled trials in adults with HIV-associated lipodystrophy | Used in approved EGRIFTA products for a specific indication |
Hexarelin differs from GHRP-6 at the second residue, where it contains D-2-methyltryptophan. That small structural change altered potency and pharmacology in development work. It does not make the compounds interchangeable.
Ipamorelin was designed for greater endocrine selectivity in early studies, but it also failed to establish a marketed treatment. Tesamorelin acts through the GHRH receptor and has condition-specific clinical evidence. Its approval does not validate ghrelin-receptor agonists as a class.
What claims are not established?
Current evidence does not establish hexarelin for:
- Building useful muscle, increasing strength or improving athletic performance.
- Reducing body fat, visceral fat or body weight.
- Healing tendon, ligament, muscle, bone or other injuries.
- Improving deep sleep, treating insomnia or improving daytime function.
- Reversing ageing or extending healthy life.
- Treating heart failure, cardiomyopathy or coronary disease.
- Preventing heart attacks or protecting the heart during ordinary clinical care.
- Treating growth hormone deficiency outside approved specialist pathways.
- Providing a safer substitute for prescribed growth hormone.
Some claims begin with a real observation: a growth hormone peak, a receptor signal or a short-term rise in ejection fraction. The unsupported step is turning that observation into a patient benefit that the study did not test.
What would stronger evidence require?
The first requirement would be a precisely defined product. Researchers would need to establish sequence, D and L orientation, salt, impurities, aggregates, stability and, where relevant, sterility and endotoxin control.
An early repeated-exposure study would need enough participants to measure pharmacokinetics, growth hormone, IGF-1, cortisol, prolactin, glucose and insulin over time. Pharmacokinetics means what the body does to a compound through absorption, distribution, breakdown and removal. Researchers would need to look for weakening responses, antibodies and effects that persist after exposure stops.
A treatment trial would need one medical condition and an outcome that matters to patients. A muscle trial would need strength and function, not growth hormone alone. A sleep trial would need validated sleep and daytime outcomes over more than one night. A cardiac trial would need symptoms, exercise capacity, hospital admission or survival, not only a temporary ejection-fraction change.
Participants should be randomly assigned to groups. Random assignment uses chance to reduce systematic differences between groups. A suitable placebo or active comparison would be needed, and masking should be used where possible. Masking keeps participants, researchers or outcome assessors unaware of group assignment to reduce bias.
Longer follow-up would be required for glucose control, pituitary effects, cardiovascular events, immune reactions and any concern about unwanted tissue growth. Until such evidence exists, the most accurate description is an active research compound with limited small human studies.
Frequently asked questions
What is another name for hexarelin?
Examorelin is its international non-proprietary name. EP-23905 and MF-6003 are older development codes.
How many amino acids are in hexarelin?
It contains six residues. Its sequence includes two D-amino-acid forms and a methylated tryptophan, so it is not a natural six-amino-acid human peptide.
Is hexarelin growth hormone?
No. It activates the ghrelin receptor and can prompt the pituitary to release stored growth hormone. Growth hormone is a different 191-amino-acid protein.
Is hexarelin the same as ghrelin?
No. Ghrelin is a natural hormone made mainly in the stomach. Hexarelin is a synthetic peptide that activates the same receptor despite having a different structure.
Does hexarelin increase growth hormone?
Yes. Controlled human studies show a rapid acute rise. That biomarker response does not prove lasting muscle gain, fat loss, healing or improved health.
Does hexarelin increase IGF-1?
Not reliably in the available repeated-exposure evidence. A 16-week study found no significant change in serum IGF-1 despite acute growth hormone responses.
Does hexarelin build muscle?
No controlled clinical trial has established useful gains in muscle, strength or physical function. The 16-week study did not find a significant change in lean body mass.
Does hexarelin reduce body fat?
No controlled weight-loss trial has established this. The 16-week study did not find a significant change in total body fat.
Does hexarelin improve sleep?
The direct controlled study does not support that claim. In seven healthy volunteers, hexarelin reduced slow-wave sleep and increased several hormones during the study night.
Does hexarelin protect the heart?
Small studies measured short-term increases in left ventricular ejection fraction in some groups. They did not show fewer symptoms, hospital admissions, heart attacks or deaths.
Was hexarelin studied in children?
Yes. Small older studies examined hormone responses, pituitary reserve and growth in short children. An uncontrolled eight-child study reported faster growth, but it cannot establish an approved treatment.
Does the response weaken with repeated exposure?
It can. One 16-week study found partial attenuation of the growth hormone response, which recovered towards baseline after exposure stopped.
Is hexarelin FDA approved?
No. It is not an FDA-approved medicine, and we did not identify a current EMA-authorised hexarelin product.
Is compounded hexarelin FDA approved?
No. Compounded drugs are not FDA approved. The agency does not pre-review them for safety, effectiveness and quality in the same way as approved products.
Are the administration levels in this guide recommendations?
No. They document study conditions so that the evidence can be understood. They are not personal dosing, preparation or administration advice.
Is hexarelin prohibited in sport?
Yes. WADA lists examorelin, or hexarelin, among growth hormone secretagogues prohibited at all times.
Sources
Research reviewed through September 2026.